Prospective Clinical Assessment Study in Children With Achondroplasia (ACH)
Prospective Clinical Assessment Study in Children With Achondroplasia: The PROPEL Trial
Sponsor: QED Therapeutics, a BridgeBio company
A observational or N/A phase clinical study on Achondroplasia, this trial is ongoing. The trial is conducted by QED Therapeutics, a BridgeBio company and has accumulated 27 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
27 versions recorded-
Dec 2025 — Present [monthly]
Active Not Recruiting
-
Sep 2025 — Dec 2025 [monthly]
Active Not Recruiting
-
May 2025 — Sep 2025 [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
-
Feb 2025 — May 2025 [monthly]
Recruiting
-
Sep 2024 — Feb 2025 [monthly]
Recruiting
▶ Show 22 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Recruiting
-
Jun 2024 — Jul 2024 [monthly]
Recruiting
-
May 2024 — Jun 2024 [monthly]
Recruiting
-
Mar 2024 — May 2024 [monthly]
Recruiting
-
Jan 2024 — Mar 2024 [monthly]
Recruiting
-
Nov 2023 — Jan 2024 [monthly]
Recruiting
-
Oct 2023 — Nov 2023 [monthly]
Recruiting
-
Sep 2023 — Oct 2023 [monthly]
Recruiting
-
Aug 2023 — Sep 2023 [monthly]
Recruiting
-
May 2022 — Aug 2023 [monthly]
Recruiting
-
Dec 2021 — May 2022 [monthly]
Recruiting
-
Oct 2021 — Dec 2021 [monthly]
Recruiting
-
Jan 2021 — Oct 2021 [monthly]
Recruiting
-
Nov 2020 — Jan 2021 [monthly]
Recruiting
-
Oct 2020 — Nov 2020 [monthly]
Recruiting
-
Apr 2020 — Oct 2020 [monthly]
Recruiting
-
Feb 2020 — Apr 2020 [monthly]
Recruiting
-
Jan 2020 — Feb 2020 [monthly]
Recruiting
-
Dec 2019 — Jan 2020 [monthly]
Recruiting
-
Nov 2019 — Dec 2019 [monthly]
Recruiting
-
Sep 2019 — Nov 2019 [monthly]
Recruiting
-
Aug 2019 — Sep 2019 [monthly]
Recruiting
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- QED Therapeutics, a BridgeBio company
For direct contact, visit the study record on ClinicalTrials.gov .